WO1992004335A3 - Antagonistes d'angiotensine ii a base de biphenylalkyle 1h-substitue-1,2,4-triazole a specificite renale pour le traitement de l'hypertension - Google Patents

Antagonistes d'angiotensine ii a base de biphenylalkyle 1h-substitue-1,2,4-triazole a specificite renale pour le traitement de l'hypertension Download PDF

Info

Publication number
WO1992004335A3
WO1992004335A3 PCT/US1991/005897 US9105897W WO9204335A3 WO 1992004335 A3 WO1992004335 A3 WO 1992004335A3 US 9105897 W US9105897 W US 9105897W WO 9204335 A3 WO9204335 A3 WO 9204335A3
Authority
WO
WIPO (PCT)
Prior art keywords
renal
substituted
aii
kidney
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/005897
Other languages
English (en)
Other versions
WO1992004335A2 (fr
Inventor
David B Reitz
Robert E Manning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Priority to PT9880791A priority Critical patent/PT98807A/pt
Priority to IE303891A priority patent/IE913038A1/en
Publication of WO1992004335A2 publication Critical patent/WO1992004335A2/fr
Publication of WO1992004335A3 publication Critical patent/WO1992004335A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B1/00—Details of transmission systems, not covered by a single one of groups H04B3/00 - H04B13/00; Details of transmission systems not characterised by the medium used for transmission
    • H04B1/38—Transceivers, i.e. devices in which transmitter and receiver form a structural unit and in which at least one part is used for functions of transmitting and receiving
    • H04B1/3827—Portable transceivers
    • H04B1/3883—Arrangements for mounting batteries or battery chargers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

On décrit des composés à spécificité rénale qui, dans un mode de réalisation, sont des prodrogues converties de préférence dans les reins en composés pouvant bloquer les récepteurs d'angiotensine II (AII). Ces prodrogues sont des conjugués formés à partir de deux composants, à savoir un premier composant représenté par un composé antagoniste d'AII et un deuxième composant qui peut être séparé du premier composant lorsque les deux composants sont liés chimiquement au conjugué. Les deux composants sont liés chimiquement par un lien qui est scindé sélectivement dans le rein, par exemple par une enzyme. Le composé antagoniste d'AII ainsi libéré est alors disponible pour bloquer les récepteurs d'AII dans le rein. Les conjugués présentant un intérêt particulier sont les dérivés glutamyle de composés de biphénylméthyle 1H-substitué-1,2,4-triazole, par exemple l'acide N-acétylglutamique, 5-[[4'-(3,5-dibutyl1H-1,2,4-triazol-1-yl)méthyl][1,1'-biphényl]-2-yl]]carbonylhydrazide.
PCT/US1991/005897 1990-08-28 1991-08-26 Antagonistes d'angiotensine ii a base de biphenylalkyle 1h-substitue-1,2,4-triazole a specificite renale pour le traitement de l'hypertension Ceased WO1992004335A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PT9880791A PT98807A (pt) 1990-08-28 1991-08-28 Processo para a preparacao de conjugados selectivos renais antagonistas de angiotensina ii contendo um residuo proveniente de um composto biefenilmetil-1h-substituido-1,2,4-triazole uteis para o tratamento da hipertensao
IE303891A IE913038A1 (en) 1990-08-28 1991-08-28 Renal-selective biphenylalkyl 1h-substituted-1,2,4-triazole¹angiotensin ii antagonists for treatment of hypertension

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/574,314 US5217985A (en) 1990-08-28 1990-08-28 Renal-selective biphenylalkyl 1h-substituted-1,2,4-triazole angiotensin ii antagonists for treatment of hypertension
US574,314 1990-08-28

Publications (2)

Publication Number Publication Date
WO1992004335A2 WO1992004335A2 (fr) 1992-03-19
WO1992004335A3 true WO1992004335A3 (fr) 1992-04-16

Family

ID=24295584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/005897 Ceased WO1992004335A2 (fr) 1990-08-28 1991-08-26 Antagonistes d'angiotensine ii a base de biphenylalkyle 1h-substitue-1,2,4-triazole a specificite renale pour le traitement de l'hypertension

Country Status (4)

Country Link
US (1) US5217985A (fr)
AU (1) AU8844491A (fr)
IE (1) IE913038A1 (fr)
WO (1) WO1992004335A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0409332A3 (en) * 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
US20040121989A1 (en) * 1990-08-28 2004-06-24 G.D. Searle & Co. Renal-selective biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonists for treatment of hypertension
US7780628B1 (en) 1999-01-11 2010-08-24 Angiodynamics, Inc. Apparatus and methods for treating congestive heart disease
US7481803B2 (en) 2000-11-28 2009-01-27 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US6749598B1 (en) * 1999-01-11 2004-06-15 Flowmedica, Inc. Apparatus and methods for treating congestive heart disease
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
US7049324B1 (en) 1999-11-15 2006-05-23 Ashis Kumar Saha Triazoles as farnesyl transferase inhibitors
ATE391123T1 (de) * 1999-11-15 2008-04-15 Janssen Pharmaceutica Nv Triazole als farnesyl-transferase-hemmer
US7063679B2 (en) 2002-09-20 2006-06-20 Flowmedica, Inc. Intra-aortic renal delivery catheter
EP1585572A4 (fr) 2002-09-20 2010-02-24 Flowmedica Inc Procede et appareil pour administrer une substance intra-aortique a un vaisseau ramifie
US20060167437A1 (en) * 2003-06-17 2006-07-27 Flowmedica, Inc. Method and apparatus for intra aortic substance delivery to a branch vessel
AU2004275809A1 (en) * 2003-09-26 2005-04-07 Nitromed, Inc. Nitrosated glutamic acid compounds, compositions and methods of use
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
JP2011529072A (ja) * 2008-07-24 2011-12-01 セラヴァンス， インコーポレーテッド 二重作用血圧降下薬
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323841A2 (fr) * 1988-01-07 1989-07-12 E.I. Du Pont De Nemours And Company Antagonistes d'angiotensine II du type pyrrole, pyrazole et triazole substitués
WO1991017148A1 (fr) * 1990-05-04 1991-11-14 G.D. Searle & Co. Composes de 1,2,4-triazole a substitution 1h utilises dans le traitement de troubles cardiovasculaires

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816463A (en) * 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
CA1334092C (fr) * 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323841A2 (fr) * 1988-01-07 1989-07-12 E.I. Du Pont De Nemours And Company Antagonistes d'angiotensine II du type pyrrole, pyrazole et triazole substitués
WO1991017148A1 (fr) * 1990-05-04 1991-11-14 G.D. Searle & Co. Composes de 1,2,4-triazole a substitution 1h utilises dans le traitement de troubles cardiovasculaires

Also Published As

Publication number Publication date
IE913038A1 (en) 1992-03-11
AU8844491A (en) 1992-03-30
US5217985A (en) 1993-06-08
WO1992004335A2 (fr) 1992-03-19

Similar Documents

Publication Publication Date Title
WO1992004335A3 (fr) Antagonistes d'angiotensine ii a base de biphenylalkyle 1h-substitue-1,2,4-triazole a specificite renale pour le traitement de l'hypertension
WO1992002257A3 (fr) Antagonistes d'angiotensines ii a action selective sur les reins et utilises dans le traitement de l'hypertension
AU6158096A (en) Spironolactone and angiotensin ii antagonist combination the rapy for treatment of congestive heart failure
DE69007740D1 (de) Substituierte 5-[(Tetrazolyl)alkenyl]-Imidazole.
WO1996040255A3 (fr) Procede de traitement de la fibrose cardiaque par une combinaison therapeutique d'un antagoniste de l'angiotensine ii et d'un antagoniste de l'aldosterone epoxy-steroide
EP1138334A3 (fr) Procédés et composés de préciblage
AU1286001A (en) Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
EA199800873A1 (ru) Дигидрат эпросартана и способ его получения и готовая препаративная форма
WO2002022627A3 (fr) Ligands pour recepteurs metabotropiques du glutamate et inhibiteurs de la naaladase
HU9300618D0 (en) Imidazole derivatives containing biphenyl-sulfonyl-urea side chain or biphenyl-sulfonyl-urethane one as well as method for producing them and their utilization
WO1992000067A3 (fr) Traitement de l'insuffisance renale chronique a l'aide d'imidazoles antagonistes des recepteurs d'angiotensine-ii
AU641952B2 (en) Substituted N-(imidazolyl)alkyl alanine derivatives
EP1384717A3 (fr) Intermediaires de l'acide Tetrazolylphenylboronique destinés à la synthèse d'agonistes du recepteur A II
EP0966975A3 (fr) Agents de diagnostiques de la fonction exocrine pancréatique
EP0296581A3 (fr) Dérivés 1,2-dicéto amino-acides comme inhibiteurs de la rénine
CA2294515A1 (fr) Eprosartane monohydrate
WO1992020651A3 (fr) Acides de n-(heteroaryle)-imidazolyle-alkenoic
EP1506914A3 (fr) Châssis reporté pour tête de traction d'un véhicle
TR200001412T2 (tr) Çok miktarda ilaç içeren, derhal ve modifike bir salgılama sağlayan oral doz formülasyonları ve bunların imal edilmesi için proses.
EP0802198A3 (fr) Pyridazino-, pyrimido, pyrazino et triazolo-indoles
CA2303217A1 (fr) Utilisation d'un antagoniste du recepteur de l'angiotensine ii pour la preparation de medicaments servant a accroitre le taux de survie des patients ayant subi une transplantationrenale
WO1996032134A3 (fr) Conjugue comprenant un principe actif, un polyether et eventuellement une proteine a l'etat natif non consideree comme exogene
WO2001043761A3 (fr) Procedes permettant de traiter et d'empecher des lesions des muqueuses
EP0936221A4 (fr) Nouveaux derives de 2,4-dioxopyrrolidine et de 2,4-dioxotetrahydrofurane et medicaments comprenant lesdits derives en tant que composant actif

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA